Breaking News
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
Research team awarded $3.6 million to assess safety of genome editing

Research team awarded $3.6 million to assess safety of genome editing

image_pdfDownload PDFimage_print

As genome editing technologies quickly advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. They are also bringing to light a number of challenges that need to be addressed before potential treatments can be widely used in patients.

To tackle these challenges and fuel efforts across the country, the National Institutes of Health (NIH) launched the Somatic Cell Genome Editing program. Among the program’s first grant recipients is a group led by Todd McDevitt, PhD, senior investigator at the Gladstone Institutes. The team was awarded more than $3.6 million over the next 5 years to assess the safety of genome editing in human cells and tissues.

Jennifer Doudna, PhD, a senior investigator at Gladstone and a professor at UC Berkeley, also received funding to expand the current toolkit for human genome editing by exploring new CRISPR-Cas proteins and enzymes that can repair DNA.

“This program is funded by the NIH’s Common Fund, indicating the importance–and promise–of genome editing technology, such as CRISPR-Cas9,” said Deepak Srivastava, MD, president of the Gladstone Institutes. “We are proud that Gladstone investigators are in a position to have a significant impact on shaping this field and its future clinical applications.”

For his project, bioengineering expert McDevitt has joined forces with another senior investigator at Gladstone, Bruce Conklin, MD, who is pioneering an approach called “genome surgery,” which reflects the precision of customizing genome therapies to individual patients.

Together, they assembled a team of leading investigators with complementary experience in tissue engineering, genome editing, gene therapy, stem cell biology, and single cell genomics. Their collaborators include Andrew May, DPhil, from the Chan Zuckerberg Biohub, as well as Luke Judge, MD, PhD, and Nicole Paulk, PhD, from UC San Francisco (UCSF).

“Our primary objective is to develop platforms that can accurately detect adverse effects of genome editing on physiological function,” said McDevitt, who is also a professor in the Department of Bioengineering and Therapeutic Sciences at UCSF. “By evaluating possible safety and toxicity issues in human cells and tissues, we hope to help avoid unanticipated effects in future clinical trials.”

Genome editing consists of making changes to a person’s DNA to remove, insert, or replace certain genes. So far, researchers have focused on exploring whether these edits are being made in the correct genes and whether other parts of the DNA are unintentionally affected.

The new project proposed by McDevitt’s group will expand current knowledge by also examining whether genome editing could lead to unexpected changes in the function of cells or tissues. More precisely, they will study the extent of DNA damage that can be tolerated before causing adverse functional consequences.

To do so, they will combine state-of-the-art methods for engineering human microtissues from stem cells with novel approaches for inducing precise genome edits and detecting any detrimental DNA damage.

McDevitt will leverage his laboratory’s expertise in developing human microtissues that faithfully mimic the way different cell types are organized and function as complex tissues. These models will serve as an ideal platform to identify and quantify adverse outcomes in response to genome editing.

“With the 3D environment of microtissues, we can study how cells cooperate and determine whether edits to one cell cause unpredicted consequences to adjacent cells,” explained McDevitt. “As a result, these tissues can be much more predictive of physiological effects than single cells grown in a dish.”

The research group will test different editing methods in heart, brain, and liver microtissues, given that all three of these tissues have relevant disease applications. For instance, many forms of heart disease and neurodegenerative diseases are caused by genetic mutations that could potentially be treated with genome editing.

“Microtissues provide an essential test prior to any human trial,” said Conklin, who is also a professor the Departments of Medical Genetics and Molecular Pharmacology at UCSF. “Since animal models are often poor predictors of activity in humans, few methods exist to determine both intended and unintended consequences of therapeutic interventions. Microtissues, however, will help predict the exact type of genome editing event that could be toxic to aide in the design and monitoring of safer clinical trials.”

For the first 3 years of the study, the research team will develop methods to detect the frequency and types of off-target genome edits that occur and correspond to specific adverse outcomes in live human cells and tissues. Then, they will use their systems to test new genome editors developed by other members of the Somatic Cell Genome Editing program to further refine and optimize their approach.

Ultimately, McDevitt, Conklin, and their collaborators will share their models for widespread use by other program members. In doing do, they hope to provide the scientific community with a critical new platform to assess both the safety and effectiveness of genome editing therapies before they are routinely tested in clinical medicine.

Source:

https://gladstone.org/about-us/press-releases/36-million-study-adverse-effects-genome-editing

Tagged with:

About author

Related Articles